Casie Shenoy, MD
Medical Oncology · Sacramento, CANPI 1306135470
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $168 of the $252 with a category attached, or 66.5%. 6 manufacturers reported payments, led by AVEO Pharmaceuticals, Inc. at 33.5% of the total. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 6 payments — averaging $42.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AVEO Pharmaceuticals, Inc.$85
- Medexus Pharma, Inc.$59
- Daiichi Sankyo Inc.$36
- Novartis$30
- Sanofi$25
- Gilead$17
Across 32 payments — averaging $13,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$418K
What the payments were for
- Food & beverage$16866%
- Education$8534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AVEO Pharmaceuticals, Inc. | 1 | $85 |
| Medexus Pharma, Inc. | 1 | $59 |
| Daiichi Sankyo Inc. | 1 | $36 |
| Novartis | 1 | $30 |
| Sanofi | 1 | $25 |
| Gilead | 1 | $17 |
How this compares
$252 in reported general payments places this provider in the 20th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 14 | $196,929 |
| ErleadaApalutamide | 11 | $145,077 |
| EliquisApixaban | 29 | $18,493 |
| Imatinib Mesylate | 13 | $1,045 |
| Raloxifene Hcl | 14 | $982 |
| Anastrozole | 49 | $919 |
| Fentanyl | 11 | $659 |
| Letrozole | 35 | $606 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $500 |
| Tamoxifen Citrate | 19 | $389 |
| Hydroxyurea | 36 | $386 |
| Gabapentin | 33 | $324 |
| Ondansetron Hcl | 22 | $314 |
| Dexamethasone | 43 | $294 |
| Acyclovir | 29 | $164 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Sacramento
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.